Kemantane is a tricyclic compound with a unique structure that has attracted interest for its potential pharmacological properties. It is synthesized through a multi-step process that involves the reaction of cyclohexane with formaldehyde and aniline. Kemantane has been investigated for its potential as an anticonvulsant and neuroprotective agent. Research studies have shown that it possesses anti-inflammatory and antioxidant effects, suggesting potential benefits in treating neurodegenerative diseases. The compound's unique structural features and biological activities make it an attractive target for further investigation and development of new therapeutic agents.'
kemantane: used in the treatment of pulmonary tuberculosis patients [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 64184 |
| CHEMBL ID | 2105062 |
| CHEBI ID | 48581 |
| SCHEMBL ID | 61676 |
| SCHEMBL ID | 19309631 |
| MeSH ID | M0186672 |
| Synonym |
|---|
| BB 0237254 |
| 4-bromo-10-oxido-1-phenazinyl methyl ether |
| 1-bromo-4-methoxyphenazine 5-oxide |
| 5-hydroxyadamantan-2-one |
| OPREA1_254797 |
| 5-hydroxytricyclo[3.3.1.1(3,7)]decanone |
| 20098-14-0 |
| idramantone |
| CHEBI:48581 , |
| kemantane |
| 5-hydroxy-2-adamantone |
| FT-0659076 |
| H0962 |
| AKOS001031795 |
| HMS3264D04 |
| EN300-54117 |
| unii-7j4759y5j1 |
| nsc 760375 |
| tricyclo(3.3.1.13,7)decanone, 5-hydroxy- |
| idramantone [inn] |
| 7j4759y5j1 , |
| tox21_112380 |
| cas-20098-14-0 |
| dtxcid6026581 |
| dtxsid8046581 , |
| nsc760375 |
| pharmakon1600-01506164 |
| nsc-760375 |
| 5-hydroxy-adamantan-2-one |
| (1r,3s)-5-hydroxyadamantan-2-one;5-hydroxy-2-adamantanone |
| CHEMBL2105062 |
| kemantan |
| S4529 |
| AM84690 |
| tricyclo(3.3.1.sup(13,7))decan-2-one, 5-hydroxy- |
| CCG-213971 |
| SCHEMBL61676 |
| 5-hydroxy-2-admantanone |
| 4-oxoadamantan-1-ol |
| 5-hydroxyadamantane-2-on |
| 5-hydroxy adamantanone |
| 4-oxo-1-adamantanol |
| 5-hydroxyadmantan-2-one |
| 5-hydroxytricyclo[3.3.1.13,7 ]decan-2-one |
| 1-hydroxy-4-adamantanone |
| 1-hydroxyadamantane-4-one |
| 5-hydroxy -2-adamantanone |
| AKOS016038251 |
| CS-4565 |
| SY032209 |
| adamantan-4-on-1-ol |
| AC-24311 |
| HY-B1044 |
| AB01563368_01 |
| tricyclo[3.3.1.13,7]decanone, 5-hydroxy- |
| SR-01000944271-1 |
| sr-01000944271 |
| AE-641/20320060 |
| SCHEMBL19309631 |
| idramantone, 20098-14-0, |
| Q27104617 |
| AS-12160 |
| HMS3885P06 |
| tricyclo[3.3.1.13,7]decan-2-one, 5-hydroxy- |
| PB41721 |
| Z56782275 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| adamantanones | A member of the class of adamantanes that is adamantane carrying at least one oxo group at unspecified position. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||